Segall Bryant & Hamill’s Collegium Pharmaceutical COLL Stock Holding History

Segall Bryant & Hamill’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Buy	30,116 +7,797	+35%	+$266K	0.01%	535
2026 Q1	$738K	Buy	22,319 +38	+0.2%	+$1.61K	0.01%	535
2025 Q4	$1.03M	Sell	22,281 -87	-0.4%	-$3.64K	0.01%	504
2025 Q3	$783K	Sell	22,368 -147	-0.7%	-$5.11K	0.01%	519
2025 Q2	$666K	Hold	22,515	–	–	0.01%	531
2025 Q1	$672K	Sell	22,515 -16,468	-42%	-$503K	0.01%	531
2024 Q4	$1.12M	Sell	38,983 -40,653	-51%	-$1.35M	0.02%	501
2024 Q3	$3.08M	Buy	79,636 +1,329	+2%	+$47.4K	0.04%	390
2024 Q2	$2.52M	Buy	+78,307	New	+$2.72M	0.04%	357

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Segall Bryant & Hamill's COLL Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Collegium Pharmaceutical (COLL) stake by 35% in Q2 2026, buying an estimated $266K and bringing the position to 30,116 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #535.

Segall Bryant & Hamill first reported a position in COLL in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.08M in Q3 2024. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Segall Bryant & Hamill held 30,116 shares of Collegium Pharmaceutical worth $1.09M as of Q2 2026.
Segall Bryant & Hamill bought 7,797 Collegium Pharmaceutical shares in Q2 2026, an estimated $266K.
Collegium Pharmaceutical made up 0.01% of Segall Bryant & Hamill's portfolio in Q2 2026, its #535 holding.
Segall Bryant & Hamill first reported a position in Collegium Pharmaceutical in Q2 2024 and has held it in 9 quarters since.
Segall Bryant & Hamill's Collegium Pharmaceutical position peaked at $3.08M in Q3 2024.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.